Albert Nathan is a seasoned sales leader at CSL, currently serving as the Area Manager for Rare Diseases, specifically focusing on Coagulation, Critical Care, and Immunology across Quebec and Atlantic Canada. With a robust background in the bio-pharmaceutical and pharmaceutical markets, Albert has honed his...
Albert Nathan is a seasoned sales leader at CSL, currently serving as the Area Manager for Rare Diseases, specifically focusing on Coagulation, Critical Care, and Immunology across Quebec and Atlantic Canada. With a robust background in the bio-pharmaceutical and pharmaceutical markets, Albert has honed his expertise in managing complex sales processes within the rare disease specialty environment, particularly in areas such as Hereditary Angioedema (HAE), Hemophilia A and B, and Immunodeficiency disorders. His strategic approach combines innovative sales techniques with a patient-centric focus, fostering strong relationships with key stakeholders, including Immuno-Allergists and Hemato-Oncologists.
One of Albert's key achievements includes the successful implementation of the Subcutaneous Immunoglobulin (Scig) replacement program, which has significantly improved patient outcomes and accessibility to treatment. His extensive network within the rare disease community, coupled with his deep understanding of hospital sales dynamics, positions him as a vital resource for healthcare professionals navigating the complexities of treatment options for patients with rare conditions.
Albert's skill set encompasses critical areas such as sales management, product launch, and key account management, making him a valuable asset to CSL. His commitment to education and collaboration with teaching hospitals further enhances his ability to drive awareness and adoption of innovative therapies. As he continues to lead initiatives in the rare disease space, Albert remains dedicated to improving the lives of patients through effective treatment solutions and robust support programs.
